Profile data is unavailable for this security.
About the company
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
- Revenue in USD (TTM)343.53m
- Net income in USD-12.24m
- Incorporated2007
- Employees761.00
- LocationCastle Biosciences Inc1500 W. Parkwood Ave., Suite 401FRIENDSWOOD 77546United StatesUSA
- Phone+1 (281) 796-9032
- Fax+1 (302) 636-5454
- Websitehttps://castlebiosciences.com/
More ▼
Mergers & acquisitions
| Acquired company | CSTL:NMQ since announced | Transaction value |
|---|---|---|
| Capsulomics Inc | 64.86% | -- |
Data delayed at least 15 minutes, as of Feb 12 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Embecta Corp | 1.08bn | 139.50m | 592.20m | 1.85k | 4.23 | -- | 3.27 | 0.5485 | 2.37 | 2.37 | 18.31 | -10.35 | 0.9757 | 2.27 | 6.35 | 583,621.60 | 12.61 | 16.69 | 16.60 | 22.65 | 63.17 | 66.74 | 12.92 | 15.71 | 1.87 | 3.18 | 1.79 | 13.07 | -3.80 | -0.1033 | 21.84 | -25.93 | -26.03 | -- |
| Beta Bionics Inc | 88.57m | -77.84m | 596.53m | 404.00 | -- | 2.02 | -- | 6.74 | -2.07 | -2.07 | 2.21 | 6.70 | 0.4149 | 2.54 | 8.16 | 304,364.30 | -36.46 | -- | -40.57 | -- | 54.51 | -- | -87.89 | -- | 9.83 | -- | 0.00 | -- | 442.93 | -- | -24.17 | -- | -- | -- |
| Alpha Tau Medical Ltd | 0.00 | -39.97m | 616.46m | 125.00 | -- | 7.95 | -- | -- | -0.5212 | -0.5212 | 0.00 | 0.9099 | 0.00 | -- | -- | 0.00 | -40.90 | -34.28 | -44.43 | -36.47 | -- | -- | -- | -- | -- | -- | 0.0735 | -- | -- | -- | -8.89 | -- | 11.60 | -- |
| SI-Bone Inc | 193.58m | -21.76m | 650.00m | 349.00 | -- | 3.77 | -- | 3.36 | -0.5113 | -0.5113 | 4.55 | 3.98 | 0.8393 | 1.29 | 7.53 | 554,664.80 | -9.43 | -24.17 | -10.61 | -26.87 | 79.62 | 82.72 | -11.24 | -40.93 | 6.62 | -- | 0.1711 | -- | 20.37 | 19.96 | 28.67 | -- | 33.83 | -- |
| Bioventus Inc | 563.83m | 7.82m | 670.38m | 950.00 | 72.11 | 4.04 | 11.69 | 1.19 | 0.1123 | 0.1123 | 8.39 | 2.01 | 0.7666 | 1.95 | 4.47 | 606,267.80 | 1.31 | -6.29 | 1.89 | -8.49 | 67.76 | 67.40 | 1.71 | -12.07 | 1.14 | 1.73 | 0.616 | -- | 11.89 | 11.00 | 65.33 | -- | -15.55 | -- |
| Avanos Medical Inc | 699.90m | -468.60m | 685.14m | 2.23k | -- | 0.8806 | -- | 0.9789 | -10.18 | -10.18 | 15.09 | 16.76 | 0.5139 | 2.14 | 5.76 | 314,279.30 | -34.41 | -4.82 | -39.66 | -5.42 | 52.28 | 54.01 | -66.95 | -11.32 | 1.36 | 8.92 | 0.1167 | -- | 2.15 | -0.2826 | -3,802.02 | -- | -18.86 | -- |
| CeriBell Inc | 82.81m | -52.46m | 739.69m | 281.00 | -- | 4.50 | -- | 8.93 | -1.45 | -1.45 | 2.29 | 4.43 | 0.6717 | 1.54 | 6.36 | 294,708.20 | -42.55 | -- | -48.06 | -- | 87.99 | -- | -63.35 | -- | 12.25 | -29.42 | 0.1074 | -- | 44.71 | -- | -37.30 | -- | -- | -- |
| Butterfly Network Inc | 88.45m | -79.87m | 770.44m | 190.00 | -- | 3.78 | -- | 8.71 | -0.3347 | -0.3347 | 0.3729 | 0.8071 | 0.3186 | 0.7409 | 3.93 | 465,515.80 | -28.77 | -- | -34.57 | -- | 43.24 | -- | -90.31 | -190.03 | 3.56 | -- | 0.00 | -- | 24.52 | -- | 45.78 | -- | -- | -- |
| STAAR Surgical Co | 230.59m | -96.37m | 820.24m | 1.16k | -- | 2.30 | -- | 3.56 | -1.96 | -1.96 | 4.64 | 7.17 | 0.464 | 1.29 | 2.80 | 199,300.80 | -19.39 | 3.81 | -22.26 | 4.42 | 73.87 | 77.03 | -41.79 | 5.42 | 4.35 | -- | 0.00 | 0.00 | -2.64 | 15.89 | -194.66 | -- | 18.11 | -- |
| Integra Lifesciences Holdings Corp | 1.64bn | -495.34m | 842.01m | 4.40k | -- | 0.8109 | -- | 0.5125 | -6.46 | -6.46 | 21.45 | 13.33 | 0.4261 | 1.52 | 6.34 | 373,741.10 | -12.85 | 2.90 | -15.39 | 3.25 | 57.21 | 62.59 | -30.15 | 7.14 | 1.80 | 2.68 | 0.6383 | 0.00 | 4.47 | 1.20 | -110.25 | -- | -3.19 | -- |
| Inmode Ltd | 370.50m | 93.83m | 906.03m | 660.00 | 9.91 | 1.33 | 9.58 | 2.45 | 1.44 | 1.44 | 5.67 | 10.78 | 0.4774 | 1.19 | 9.28 | 561,356.10 | 12.09 | 24.21 | 13.30 | 26.82 | 78.54 | 82.36 | 25.33 | 38.64 | 8.83 | -- | 0.00 | 0.00 | -6.16 | 12.44 | -48.24 | 4.57 | 15.99 | -- |
| Castle Biosciences Inc | 343.53m | -12.24m | 931.12m | 761.00 | -- | 1.99 | 30.50 | 2.71 | -0.4533 | -0.4533 | 11.67 | 16.02 | 0.6377 | 9.05 | 6.89 | 451,419.20 | -2.27 | -6.95 | -2.50 | -7.52 | 79.94 | 80.76 | -3.56 | -17.49 | 6.31 | -- | 0.0218 | -- | 51.09 | 44.97 | 131.75 | 43.57 | 97.74 | -- |
| BioLife Solutions Inc | 88.83m | -13.99m | 1.04bn | 159.00 | -- | 2.93 | -- | 11.70 | -0.2922 | -0.061 | 1.87 | 7.37 | 0.2296 | 0.8875 | 6.18 | 558,698.10 | -3.62 | -1.92 | -3.92 | -2.10 | 70.02 | 52.54 | -15.75 | -9.06 | 3.64 | -- | 0.0207 | -- | 8.44 | 24.62 | 38.27 | -- | 19.15 | -- |
| Enovis Corp | 2.23bn | -1.37bn | 1.25bn | 7.37k | -- | 0.6201 | -- | 0.5611 | -24.20 | -24.20 | 39.35 | 35.33 | 0.4474 | 1.56 | 5.37 | 303,144.60 | -27.38 | -3.14 | -30.81 | -3.56 | 57.19 | 52.01 | -61.19 | -9.77 | 1.16 | 0.0495 | 0.4018 | -- | 23.46 | -8.73 | -1,423.10 | -- | 7.58 | -- |
| Tandem Diabetes Care Inc | 1.01bn | -203.37m | 1.27bn | 2.65k | -- | 9.53 | -- | 1.26 | -3.05 | -3.05 | 15.08 | 1.96 | 1.10 | 3.25 | 8.64 | 380,000.40 | -22.20 | -10.11 | -30.80 | -12.33 | 53.23 | 51.67 | -20.20 | -11.71 | 1.90 | -9.88 | 0.7028 | -- | 25.74 | 21.01 | 56.86 | -- | 27.42 | -- |
Data as of Feb 12 2026. Currency figures normalised to Castle Biosciences Inc's reporting currency: US Dollar USD
42.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.39m | 8.18% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.98m | 6.78% |
| Principal Global Investors LLCas of 31 Dec 2025 | 1.81m | 6.19% |
| Portolan Capital Management LLCas of 30 Sep 2025 | 1.52m | 5.19% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 1.14m | 3.92% |
| Braidwell LPas of 30 Sep 2025 | 822.74k | 2.82% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 724.08k | 2.48% |
| Geode Capital Management LLCas of 30 Sep 2025 | 698.61k | 2.39% |
| Wasatch Advisors LPas of 30 Sep 2025 | 669.12k | 2.29% |
| Palisade Capital Management LPas of 30 Sep 2025 | 638.66k | 2.19% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
